
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)
Lisa A. Carey, MD, associate professor, Breast Cancer Hematology/Oncology at UNC Lineberger Comprehensive Cancer Center discusses the need for targeted therapy in triple negative breast cancer






